Phathom Pharmaceuticals, Inc. (PHAT): Cash & Equivalents
$129.97M
As of 2025-12-31
$182.48M
As of 2026-06-30
-5.8%
3-year compound annual growth
-14.7%
5-year compound annual growth
| Period ended | Cash & Equivalents | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $129.97M | -56.3% | 2026-02-26, Balance as of period end |
| 2024-12-31 | $297.26M | -22.1% | 2026-02-26, Balance as of period end |
| 2023-12-31 | $381.39M | +145.5% | 2025-03-06, Balance as of period end |
| 2022-12-31 | $155.38M | -15.2% | 2024-06-14, Balance as of period end |
| 2021-12-31 | $183.26M | -36.3% | 2023-02-28, Balance as of period end |
| 2020-12-31 | $287.50M | +17.9% | 2022-03-01, Balance as of period end |
| 2019-12-31 | $243.76M | n/m | 2021-03-30, Balance as of period end |
| 2018-12-31 | $879.0K | n/a | 2020-03-19, Balance as of period end |
Cash & Equivalents at similar companies
| Company | Year ended | Cash & Equivalents | Change YoY |
|---|---|---|---|
| Phathom Pharmaceuticals, Inc. (PHAT) | 2025-12-31 | $129.97M | -56.3% |
| Cryoport, Inc. (CYRX) | 2025-12-31 | $250.49M | +633.8% |
| Syndax Pharmaceuticals Inc (SNDX) | 2025-12-31 | $134.93M | -12.4% |
| Lifevantage Corp (LFVN) | 2025-06-30 | $20.20M | +19.6% |
| Stoke Therapeutics, Inc. (STOK) | 2025-12-31 | $84.22M | -34.2% |
| Maravai Lifesciences Holdings, Inc. (MRVI) | 2025-12-31 | $216.89M | -32.7% |
| Rhythm Pharmaceuticals, Inc. (RYTM) | 2025-12-31 | $54.30M | -39.1% |
| Liquidia Corp (LQDA) | 2025-12-31 | $190.68M | +8.0% |
| Heron Therapeutics, Inc. (HRTX) | 2025-12-31 | $28.65M | +11.0% |
Compare PHAT, CYRX, SNDX, LFVN side by side · Screen every company in Pharmaceutical Preparations ↗